BML Capital Management
Latest statistics and disclosures from BML Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SGOV, AVIR, BIL, Adverum Biotechnologies, ACRS, and represent 60.24% of BML Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Adverum Biotechnologies (+$12M), ACRS (+$11M), TIL, PMVP, RPHM, Lenz Therapeutics, Cyteir Therapeutics, Q32 Bio, AVIR, MIST.
- Started 6 new stock positions in ALVR, Lenz Therapeutics, Q32 Bio, Adverum Biotechnologies, TIL, PMVP.
- Reduced shares in these 10 stocks: TRML (-$6.4M), Theseus Pharmaceuticals, ANF, Adverum Biotechnologies, Rain Therapeutics, ATHA, ORMP, Graphite Bio, QQQ, DSGN.
- Sold out of its positions in Adverum Biotechnologies, BBW, Graphite Bio, Homology Medicines, QQQ, NGNE, Rain Therapeutics, Theseus Pharmaceuticals, TRML.
- BML Capital Management was a net buyer of stock by $7.6M.
- BML Capital Management has $152M in assets under management (AUM), dropping by 14.87%.
- Central Index Key (CIK): 0001616824
Tip: Access up to 7 years of quarterly data
Positions held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BML Capital Management
BML Capital Management holds 32 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ishares Tr 0-3 Mnth Treasry (SGOV) | 17.9 | $27M | 270k | 100.71 |
|
|
| Atea Pharmaceuticals (AVIR) | 14.7 | $22M | 5.5M | 4.04 |
|
|
| Spdr Ser Tr Bloomberg 1-3 Mo (BIL) | 12.1 | $18M | 200k | 91.80 |
|
|
| Adverum Biotechnologies Com New | 7.8 | $12M | NEW | 833k | 14.14 |
|
| Aclaris Therapeutics (ACRS) | 7.7 | $12M | +1338% | 9.4M | 1.24 |
|
| Cyteir Therapeutics | 7.3 | $11M | +12% | 3.7M | 3.01 |
|
| Eliem Therapeutics (ELYM) | 4.0 | $6.0M | 2.2M | 2.74 |
|
|
| Avrobio Ord (AVRO) | 3.4 | $5.1M | 4.0M | 1.28 |
|
|
| Instil Bio Com New (TIL) | 2.5 | $3.8M | NEW | 349k | 10.80 |
|
| Reneo Pharmaceuticals (RPHM) | 2.4 | $3.6M | +65% | 2.2M | 1.66 |
|
| Connect Biopharma Hldgs Ads (CNTB) | 2.4 | $3.6M | 2.1M | 1.74 |
|
|
| Design Therapeutics (DSGN) | 2.3 | $3.5M | -14% | 880k | 4.03 |
|
| Athira Pharma (ATHA) | 1.6 | $2.5M | -38% | 900k | 2.74 |
|
| Oramed Pharmaceuticals Com New (ORMP) | 1.6 | $2.5M | -33% | 845k | 2.92 |
|
| Pmv Pharmaceuticals (PMVP) | 1.5 | $2.2M | NEW | 1.3M | 1.70 |
|
| Astrotech Corp (ASTC) | 1.3 | $2.0M | 220k | 8.95 |
|
|
| Wingstop Put Option (WING) | 1.2 | $1.8M | -11% | 800.00 | 2286.25 |
|
| Lenz Therapeutics | 0.9 | $1.4M | NEW | 64k | 22.33 |
|
| Kinnate Biopharma (KNTE) | 0.9 | $1.3M | +6% | 499k | 2.66 |
|
| Arca Biopharma (ABIO) | 0.8 | $1.2M | 707k | 1.76 |
|
|
| Forte Biosciences (FBRX) | 0.8 | $1.2M | 1.8M | 0.70 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.7 | $1.1M | +37% | 606k | 1.79 |
|
| Verrica Pharmaceuticals (VRCA) | 0.7 | $1.1M | 180k | 5.92 |
|
|
| Lisata Therapeutics (LSTA) | 0.6 | $888k | +5% | 285k | 3.12 |
|
| Enliven Therapeutics (ELVN) | 0.6 | $881k | 50k | 17.59 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.5 | $792k | 150k | 5.28 |
|
|
| Nextcure (NXTC) | 0.5 | $683k | 307k | 2.23 |
|
|
| Calcimedica Com New (CALC) | 0.4 | $667k | +10% | 160k | 4.16 |
|
| Abercrombie & Fitch Cl A Put Option (ANF) | 0.3 | $470k | -88% | 100.00 | 4700.00 |
|
| Q32 Bio | 0.3 | $424k | NEW | 25k | 17.04 |
|
| Talis Biomedical Corp Com New (TLIS) | 0.2 | $374k | 43k | 8.75 |
|
|
| Allovir (ALVR) | 0.1 | $151k | NEW | 201k | 0.75 |
|
Past Filings by BML Capital Management
SEC 13F filings are viewable for BML Capital Management going back to 2022
- BML Capital Management 2024 Q1 restated filed April 24, 2024
- BML Capital Management 2024 Q1 filed April 23, 2024
- BML Capital Management 2023 Q4 restated filed Feb. 2, 2024
- BML Capital Management 2023 Q4 filed Jan. 30, 2024
- BML Capital Management 2023 Q3 filed Oct. 23, 2023
- BML Capital Management 2023 Q2 filed July 24, 2023
- BML Capital Management 2023 Q1 filed April 14, 2023
- BML Capital Management 2022 Q4 filed Feb. 13, 2023